查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829858

2025年癌症诊断全球市场报告

Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，癌症诊断市场规模强劲成长，从2024年的232.4亿美元成长到2025年的255亿美元，复合年增长率为9.7%。预测期内的成长归因于癌症发生率的上升、癌症筛检计画、个人化医疗以及公众意识的提升。

预计未来几年癌症诊断市场将快速成长，到2029年将达到400.7亿美元，年复合成长率（CAGR）为12.0%。预测期内的成长可归因于新兴市场的成长、监管支援、人工智慧 (AI) 和机器学习以及早期检测和介入。预测期内的主要趋势包括液态切片、多组体学方法、就地检验、筛检和早期疗育宣传活动。

癌症诊断涵盖用于检测个别癌症存在的流程、检测和技术。该领域涵盖多种旨在识别、分期和表征癌症的方法，以便及时有效地进行治疗。

我们在癌症诊断领域的主要产品包括伴随诊断和分子诊断。分子诊断涉及检测指示癌症存在的特定蛋白质、基因和分子的检测程序。癌症诊断方法包括切片检查、内视镜检查、肿瘤生物标记检测和影像学检查。这些诊断工具适用于多种癌症类型，包括子宫颈癌、乳癌、肝癌、血癌、肾臟癌、大肠癌、胰臟癌、卵巢癌和黑色素瘤。它们的最终用户包括癌症研究机构、诊断实验室、医院和相关组织。

2025年春季，美国关税突然上调及其引发的贸易摩擦对医疗设备产业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战进一步加剧了形势，因为由于关税而更换供应商通常需要医疗设备重新认证，导致市场准入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供癌症诊断市场统计数据，例如全球市场规模、区域份额、癌症诊断市场份额的竞争对手、详细的癌症诊断细分市场、市场趋势和商业机会，以及您在癌症诊断行业取得成功所需的数据。本癌症诊断市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

未来五年的预测成长率为12.0%，较我们先前对该市场的预测略有下降0.6%。这一下降主要源于美国与其他国家之间关税的影响，这可能会直接影响到美国，导致萤光原位杂合反应(FISH) 探针和数位病理切片扫描仪的供应链中断，而这些设备主要来自以色列和荷兰等主要地区。

癌症诊断市场的一个关键驱动因素是各类癌症的高发生率，迫使更多人接受诊断和治疗。世界卫生组织 (WHO) 的数据显示，癌症发生率的上升已使其成为全球第二大死因。美国国家癌症研究所 (NCI) 预测，到 2030 年，每年新增癌症病例将增加至 2,360 万人。

预计癌症诊断设备市场的成长将主要受到肺癌发病率上升的推动。肺癌是一种广泛传播且致命的癌症，其特征是肺组织中异常细胞不受控制地生长。癌症诊断设备在肺癌的检测、诊断和监测中发挥关键作用，帮助医护人员识别癌症的存在、确定其类型和分期，并指导治疗策略。例如，截至2023年3月，美国临床肿瘤学会 (ASCO) 旗下的线上资源网站 Cancer.Net 估计，2023年美国将新增约238,340例肺癌病例，较2022年的236,000例增加。肺癌发生率的上升是癌症诊断设备市场成长的主要驱动力。

癌症诊断市场的一个新兴趋势是使用基于人工智慧的系统进行癌症检测。人工智慧在提高乳癌和肺癌相关诊断程序中影像检测的准确性方面发挥关键作用。它的功能有助于在早期发现癌症，从而有助于提高检测的准确性。在肺癌筛检中，人工智慧的参与可以减少假阳性，最终提高癌症检测的准确性。特别是，圣地牙哥海军医疗中心和谷歌人工智慧研究院的研究人员开发了一种由人工智慧驱动的解决方案，用于自主评估淋巴结活检，将转移性乳癌检测的准确率显着提高至99%。

癌症诊断设备市场的主要企业正专注于包括人工智慧 (AI) 在内的技术进步，以在行业中建立竞争优势，例如 QAi Prostate，这是一款专门用于前列腺癌检测的尖端癌症诊断工具。值得注意的是，2023 年 3 月，总部位于新加坡的 Qritive 公司推出了 QAi Prostate，该公司专门为病理学家提供人工智慧诊断解决方案。这款创新的人工智慧工具采用机器学习演算法，能够准确地识别和分类前列腺组织样本中的良性和恶性区域。它为病理学家提供了宝贵的资源，帮助他们准确检测前列腺癌，同时区分所分析组织样本中的良性和恶性区域。

癌症诊断市场受美国食品药物管理局 (FDA) 监管，该机构对 MRI 和 NMR 等癌症诊断设备实施严格的监管。由于涉及中等风险，这些设备被归类为 II 类。此分类规定了具体的监管义务，包括性能标准、上市前资料要求、上市后监督和标籤要求。特别是，设备标籤必须包含详细信息，例如禁忌症、副作用、注意事项、警告和使用说明。这些监管措施为癌症诊断设备製造商设定了查核点。

癌症诊断市场的主要企业包括雅培实验室、碧迪公司、Hologic、通用电气医疗有限公司、赛默飞世尔科技、西门子医疗有限公司、Accuray、医科达公司、CR BardInc、Biogenex Laboratories、Eckert & Ziegler BEBIG、Veracyte、PathAI、Bio-Rad Laboratories、Bionox & Ziegler BEBIG、Veracyte、PathAI、Bio-Rad Sciences、礼来公司、Genomic Health、Affymetrix、安捷伦科技、Adaptive Biotechnologies、Biocartis、Biocept、Cancer Genetics Inc、Caris Lifesciences、Cepheid、 表观基因 AG、Exact Sciences、Foundation Medicine、Genmark Diagnostics、GuardIBant、Hanonostics、Hanod . Technologies、Natera、NeoGenomics、Oncura Inc.、PerkinElmer、Personal Genome Diagnostics， Qiagen、Roche Diagnostics、TheraGenics Corporation 和 Varian Medical Systems, Inc.

2024年，癌症诊断市场最大的地区是北美。亚太地区是全球癌症诊断市场的第二大地区。癌症诊断市场报告涵盖亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。

癌症诊断市场报告涵盖澳大利亚、中国、印度、印尼、日本、韩国、孟加拉国、泰国、越南、马来西亚、新加坡、菲律宾、香港、新西兰、美国、加拿大、墨西哥、巴西、智利、阿根廷、哥伦比亚、秘鲁、法国、德国、英国、奥地利、比利时、丹麦、芬兰、爱尔兰、意大利、荷兰、挪威、葡萄牙、西班牙、瑞典、瑞士、俄罗斯、捷克共和国、波兰、罗马尼亚、乌克兰、沙特阿拉伯、以色列、伊朗、土耳其、阿联酋、埃及、尼日利亚和南非等国家。

癌症诊断市场包括病理学设备（玻片染色系统、组织处理系统、细胞处理器、PCR设备、NGS设备和其他病理学设备）、影像设备（CT系统、超音波系统、MRI系统、乳房X光摄影系统和核子医学摄影影像系统）以及切片检查。该市场的价值是指出厂价，即商品製造商或生产商向其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接向最终客户销售的商品价值。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球癌症诊断：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球癌症诊断市场：成长率分析
  • 全球癌症诊断市场表现：规模与成长，2019-2024
  • 全球癌症诊断市场预测：规模与成长，2024-2029年，2034年
  • 全球癌症诊断：总目标市场（TAM）

第六章 市场细分

  • 全球癌症诊断市场（依产品、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 伴随诊断
  • 分子诊断
  • 全球癌症诊断市场的应用、表现与预测，2019-2024 年、2024-2029 年、2034 年
  • 切片检查
  • 内视镜检查
  • 肿瘤生物标记检测
  • 影像学
  • 全球癌症诊断市场（按癌症类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 子宫颈癌
  • 乳癌
  • 肝癌
  • 血癌
  • 肾癌
  • 大肠直肠癌
  • 胰臟癌
  • 卵巢癌
  • 黑色素瘤
  • 其他用途
  • 全球癌症诊断市场（按最终用户、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 癌症研究所
  • 诊断实验室
  • 医院
  • 其他最终用户
  • 全球癌症诊断市场：伴随诊断细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 基于生物标记的伴随诊断
  • 基于基因检测的伴随诊断
  • 基于免疫组织化学的伴随诊断
  • 基于PCR的伴随诊断
  • 其他伴随诊断
  • 全球癌症诊断市场：依分子诊断细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素链锁反应（PCR）诊断
  • 次世代定序（NGS）诊断
  • 原位杂交诊断
  • 基于微阵列的诊断
  • DNA或RNA萃取试剂套件
  • 其他分子诊断

第七章 区域和国家分析

  • 全球癌症诊断市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球癌症诊断市场：依国家、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 孟加拉市场

第十六章 泰国市场

第十七章 越南市场

第十八章 马来西亚市场

第十九章：新加坡市场

第二十章：菲律宾市场

第21章 香港市场

第22章：纽西兰市场

第23章 西欧市场

第24章英国市场

第25章：德国市场

第26章：法国市场

第27章：义大利市场

第28章：西班牙市场

第29章：西班牙市场

第30章：奥地利市场

第31章：比利时市场

第32章：丹麦市场

第33章 芬兰市场

第34章：爱尔兰市场

第35章：荷兰市场

第36章：挪威市场

第37章：葡萄牙市场

第38章：瑞典市场

第39章：瑞士市场

第四十章 东欧市场

第41章俄罗斯市场

第42章 捷克共和国市场

第43章：波兰市场

第44章：罗马尼亚市场

第45章：乌克兰市场

第46章 北美市场

第47章美国市场

第48章：加拿大市场

第50章：南美市场

第51章：巴西市场

第52章 智利市场

第53章：阿根廷市场

第54章：哥伦比亚市场

第55章秘鲁市场

第56章 中东市场

第57章：沙乌地阿拉伯市场

第58章：以色列市场

第59章 伊朗市场

第60章 土耳其市场

第61章：阿拉伯联合大公国市场

第62章 非洲市场

第63章埃及市场

第64章 尼日利亚市场

第65章南非市场

第66章：竞争格局与公司概况

  • 癌症诊断市场：竞争格局
  • 癌症诊断市场：公司简介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • Hologic Overview, Products and Services, Strategy and Financial Analysis
    • GE Healthcare Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis

第 67 章：其他领先和创新企业

  • Siemens Healthcare GmbH
  • Accuray
  • Elekta AB
  • CR Bard Inc.
  • Biogenex Laboratories
  • Eckert & Ziegler BEBIG
  • Veracyte
  • PathAI
  • Bio-Rad Laboratories
  • Biochain
  • DiagnoCure
  • Illumina
  • Myriad Genetics
  • CompanionDx
  • Epic Sciences

第 68 章：全球市场竞争基准化分析与仪錶板

第69章：重大併购

第70章近期市场趋势

第71章：高潜力市场国家、细分市场与策略

  • 2029年癌症诊断市场：提供新机会的国家
  • 2029年癌症诊断市场：细分领域带来新机会
  • 2029年癌症诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第72章 附录

简介目录
Product Code: r32435u

Cancer diagnostics involves the processes, tests, and technologies used to detect the presence of cancer in individuals. This area includes various methods aimed at identifying, staging, and characterizing cancer, enabling timely and effective treatment.

The primary offerings within the cancer diagnostics sector include companion diagnostics and molecular diagnostics. Molecular diagnostics involve laboratory procedures to detect particular proteins, genes, or molecules indicating the presence of cancer. Diagnostic methods in cancer assessments encompass biopsies, endoscopies, tumor biomarker tests, and imaging. These diagnostic tools cater to various applications, including cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others. They are utilized by diverse end-users like cancer research institutes, diagnostic laboratories, hospitals, and related entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer diagnostics market size has grown strongly in recent years. It will grow from $23.24 billion in 2024 to $25.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing cancer incidence, cancer screening programs, personalized medicine, public awareness.

The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $40.07 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to emerging markets growth, regulatory support, artificial intelligence (ai) and machine learning, early detection and intervention. Major trends in the forecast period include liquid biopsies, multi-omics approaches, point-of-care testing, screening and early intervention campaigns.

The forecast of 12.0% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for fluorescence in situ hybridization (FISH) probes and digital pathology slide scanners, sourced from key regions such as Israel and the Netherlands, which could lead to reduced testing capacity and increased oncology care costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The significant driver behind the cancer diagnostics market is the high prevalence of various cancer types, compelling a larger number of individuals to seek diagnosis and treatment. These escalating cancer incidents have led to cancer becoming the second most common cause of death globally, as per the World Health Organization (WHO). Projections by the National Cancer Institute (NCI) estimate new annual cancer cases to increase to 23.6 million by the year 2030.

The growth of the cancer diagnostic device market is anticipated to be significantly propelled by the rising incidence of lung cancer. Lung cancer, characterized by the uncontrolled growth of abnormal cells in lung tissues, is a prevalent and deadly form of cancer. Cancer diagnostic devices play a crucial role in detecting, diagnosing, and monitoring lung cancer, aiding healthcare professionals in identifying its presence, determining its type and stage, and guiding treatment strategies. For example, as of March 2023, Cancer.Net, an online resource affiliated with the American Society of Clinical Oncology (ASCO), has estimated that the United States will witness around 238,340 new cases of lung cancer in 2023, an increase from the 236,000 cases diagnosed in 2022. This escalating incidence of lung cancer is a key driver for the growth of the cancer diagnostic device market.

The emerging trend within the cancer diagnostics market is the utilization of AI-based systems for cancer detection. AI plays a pivotal role in enhancing the precision of image detection in diagnostic procedures related to breast and lung cancer. Its capabilities aid in identifying cancers during their early stages, thereby contributing to improved detection accuracy. In lung cancer screening, AI's involvement results in a reduction in false-positive occurrences, ultimately enhancing accuracy in cancer detection. Notably, researchers at the Naval Medical Center San Diego and Google AI research division developed an AI-driven solution for autonomous evaluation of lymph node biopsies, significantly enhancing metastatic breast cancer detection accuracy to 99%.

Prominent companies within the cancer diagnostic device market are directing their efforts toward technological advancements involving artificial intelligence (AI), as seen with QAi Prostate, to establish a competitive advantage in the industry. QAi Prostate is a cutting-edge cancer diagnostic tool specifically designed for prostate cancer detection. Notably, in March 2023, Qritive, a Singapore-based enterprise specializing in AI-powered diagnostic solutions for pathologists, introduced QAi Prostate. This innovative AI-driven tool employs machine learning algorithms to precisely recognize and categorize malignant and benign regions within prostate tissue samples. It serves as a valuable resource for pathologists, aiding in the accurate detection of prostate cancer while distinguishing between malignant and benign areas in the analyzed tissue samples.

The cancer diagnostics market is overseen by the FDA, which applies stringent regulations to cancer diagnostic devices like MRI and NMR. These devices fall under the Class II category due to their moderate associated risk. This classification subjects them to specific regulatory mandates encompassing performance standards, premarket data requirements, post-market surveillance, and necessary labelling conditions. Notably, device labelling must include details like contraindications, adverse reactions, precautions, warnings, and usage instructions. Such regulatory measures serve as a checkpoint for manufacturers producing cancer diagnostic devices.

Major companies operating in the cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Elekta AB, C.R. BardInc., Biogenex Laboratories, Eckert & Ziegler BEBIG, Veracyte, PathAI, Bio-Rad Laboratories, Biochain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Eli Lilly and Co, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, IBA group, Invitae Corporation, Medtronic PLC, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics, Theragenics Corporation, Varian Medical SystemsInc.

North America was the largest region in the cancer diagnostics market in 2024. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer diagnostics market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Products: Companion Diagnostics; Molecular Diagnostics
  • 2) By Method: Biopsy; Endoscopy; Tumor Biomarker Tests; Imaging
  • 3) By Application: Cervical Cancer; Breast Cancer; Liver Cancer; Blood Cancer; Kidney Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Melanoma; Other Applications
  • 4) By End-User: Cancer Research Institutes; Diagnostic Laboratories; Hospitals; Other End Users
  • Subsegments:
  • 1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics; Genetic Testing-Based Companion Diagnostics; Immunohistochemistry-Based Companion Diagnostics; PCR-Based Companion Diagnostics; Other Companion Diagnostics;
  • 2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics; Next-Generation Sequencing (NGS) Diagnostics; In Situ Hybridization Diagnostics; Microarray-Based Diagnostics; DNA Or RNA Extraction Kits; Other Molecular Diagnostics
  • Companies Mentioned: Abbott Laboratories; Becton Dickinson and Company; Hologic; GE Healthcare Ltd.; Thermo Fisher Scientific; Siemens Healthcare GmbH; Accuray; Elekta AB; C.R. BardInc.; Biogenex Laboratories; Eckert & Ziegler BEBIG; Veracyte; PathAI; Bio-Rad Laboratories; Biochain; DiagnoCure; Illumina; Myriad Genetics; CompanionDx; Epic Sciences; Eli Lilly and Co; Genomic Health; Affymetrix; Agilent Technologies; Adaptive Biotechnologies; Biocartis; Biocept; Cancer Genetics Inc.; Caris Life Sciences; Cepheid; Epigenomics AG; Exact Sciences; Foundation Medicine; GenMark Diagnostics; Guardant Health; HalioDX; IBA group; Invitae Corporation; Medtronic plc; NanoString Technologies; Natera; NeoGenomics; Oncura Inc.; PerkinElmer; Personal Genome Diagnostics; Qiagen; Roche Diagnostics; Theragenics Corporation; Varian Medical SystemsInc.
  • Countries: Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Diagnostics Market Characteristics

3. Cancer Diagnostics Market Trends And Strategies

4. Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cancer Diagnostics Total Addressable Market (TAM)

6. Cancer Diagnostics Market Segmentation

  • 6.1. Global Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Companion Diagnostics
  • Molecular Diagnostics
  • 6.2. Global Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopsy
  • Endoscopy
  • Tumor Biomarker Tests
  • Imaging
  • 6.3. Global Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cervical Cancer
  • Breast Cancer
  • Liver Cancer
  • Blood Cancer
  • Kidney Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Melanoma
  • Other Applications
  • 6.4. Global Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users
  • 6.5. Global Cancer Diagnostics Market, Sub-Segmentation Of Companion Diagnostics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biomarker-Based Companion Diagnostics
  • Genetic Testing-Based Companion Diagnostics
  • Immunohistochemistry-Based Companion Diagnostics
  • PCR-Based Companion Diagnostics
  • Other Companion Diagnostics
  • 6.6. Global Cancer Diagnostics Market, Sub-Segmentation Of Molecular Diagnostics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR) Diagnostics
  • Next-Generation Sequencing (NGS) Diagnostics
  • In Situ Hybridization Diagnostics
  • Microarray-Based Diagnostics
  • DNA Or RNA Extraction Kits
  • Other Molecular Diagnostics

7. Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Diagnostics Market

  • 8.1. Asia-Pacific Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Diagnostics Market

  • 9.1. China Cancer Diagnostics Market Overview
  • 9.2. China Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Diagnostics Market

  • 10.1. India Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Diagnostics Market

  • 11.1. Japan Cancer Diagnostics Market Overview
  • 11.2. Japan Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Diagnostics Market

  • 12.1. Australia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Diagnostics Market

  • 13.1. Indonesia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Diagnostics Market

  • 14.1. South Korea Cancer Diagnostics Market Overview
  • 14.2. South Korea Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Bangladesh Cancer Diagnostics Market

  • 15.1. Bangladesh Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.2. Bangladesh Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Bangladesh Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. Thailand Cancer Diagnostics Market

  • 16.1. Thailand Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. Thailand Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. Thailand Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Vietnam Cancer Diagnostics Market

  • 17.1. Vietnam Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Vietnam Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Vietnam Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. Malaysia Cancer Diagnostics Market

  • 18.1. Malaysia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. Malaysia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. Malaysia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Singapore Cancer Diagnostics Market

  • 19.1. Singapore Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Singapore Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Singapore Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Philippines Cancer Diagnostics Market

  • 20.1. Philippines Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Philippines Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Philippines Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Hong Kong Cancer Diagnostics Market

  • 21.1. Hong Kong Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.2. Hong Kong Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Hong Kong Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. New Zealand Cancer Diagnostics Market

  • 22.1. New Zealand Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. New Zealand Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. New Zealand Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. Western Europe Cancer Diagnostics Market

  • 23.1. Western Europe Cancer Diagnostics Market Overview
  • 23.2. Western Europe Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. Western Europe Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. Western Europe Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. UK Cancer Diagnostics Market

  • 24.1. UK Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.2. UK Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. UK Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Germany Cancer Diagnostics Market

  • 25.1. Germany Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.2. Germany Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Germany Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. France Cancer Diagnostics Market

  • 26.1. France Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.2. France Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. France Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Italy Cancer Diagnostics Market

  • 27.1. Italy Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Italy Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Italy Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Spain Cancer Diagnostics Market

  • 28.1. Spain Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.2. Spain Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Spain Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Spain Cancer Diagnostics Market

  • 29.1. Spain Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.2. Spain Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Spain Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Austria Cancer Diagnostics Market

  • 30.1. Austria Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 30.2. Austria Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 30.3. Austria Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

31. Belgium Cancer Diagnostics Market

  • 31.1. Belgium Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 31.2. Belgium Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 31.3. Belgium Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

32. Denmark Cancer Diagnostics Market

  • 32.1. Denmark Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 32.2. Denmark Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 32.3. Denmark Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

33. Finland Cancer Diagnostics Market

  • 33.1. Finland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 33.2. Finland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 33.3. Finland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

34. Ireland Cancer Diagnostics Market

  • 34.1. Ireland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 34.2. Ireland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 34.3. Ireland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

35. Netherlands Cancer Diagnostics Market

  • 35.1. Netherlands Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 35.2. Netherlands Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 35.3. Netherlands Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

36. Norway Cancer Diagnostics Market

  • 36.1. Norway Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 36.2. Norway Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 36.3. Norway Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

37. Portugal Cancer Diagnostics Market

  • 37.1. Portugal Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 37.2. Portugal Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 37.3. Portugal Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

38. Sweden Cancer Diagnostics Market

  • 38.1. Sweden Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 38.2. Sweden Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 38.3. Sweden Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

39. Switzerland Cancer Diagnostics Market

  • 39.1. Switzerland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 39.2. Switzerland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 39.3. Switzerland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

40. Eastern Europe Cancer Diagnostics Market

  • 40.1. Eastern Europe Cancer Diagnostics Market Overview
  • 40.2. Eastern Europe Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 40.3. Eastern Europe Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 40.4. Eastern Europe Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

41. Russia Cancer Diagnostics Market

  • 41.1. Russia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 41.2. Russia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 41.3. Russia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

42. Czech Republic Cancer Diagnostics Market

  • 42.1. Czech Republic Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 42.2. Czech Republic Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 42.3. Czech Republic Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

43. Poland Cancer Diagnostics Market

  • 43.1. Poland Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 43.2. Poland Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 43.3. Poland Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

44. Romania Cancer Diagnostics Market

  • 44.1. Romania Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 44.2. Romania Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 44.3. Romania Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

45. Ukraine Cancer Diagnostics Market

  • 45.1. Ukraine Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 45.2. Ukraine Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 45.3. Ukraine Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

46. North America Cancer Diagnostics Market

  • 46.1. North America Cancer Diagnostics Market Overview
  • 46.2. North America Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 46.3. North America Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 46.4. North America Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

47. USA Cancer Diagnostics Market

  • 47.1. USA Cancer Diagnostics Market Overview
  • 47.2. USA Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 47.3. USA Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 47.4. USA Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

48. Canada Cancer Diagnostics Market

  • 48.1. Canada Cancer Diagnostics Market Overview
  • 48.2. Canada Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 48.3. Canada Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 48.4. Canada Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.1. Mexico Cancer Diagnostics Market Overview
  • 49.2. Mexico Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.3. Mexico Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.4. Mexico Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

50. South America Cancer Diagnostics Market

  • 50.1. South America Cancer Diagnostics Market Overview
  • 50.2. South America Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50.3. South America Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50.4. South America Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

51. Brazil Cancer Diagnostics Market

  • 51.1. Brazil Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 51.2. Brazil Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 51.3. Brazil Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

52. Chile Cancer Diagnostics Market

  • 52.1. Chile Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 52.2. Chile Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 52.3. Chile Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

53. Argentina Cancer Diagnostics Market

  • 53.1. Argentina Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 53.2. Argentina Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 53.3. Argentina Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

54. Colombia Cancer Diagnostics Market

  • 54.1. Colombia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 54.2. Colombia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 54.3. Colombia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

55. Peru Cancer Diagnostics Market

  • 55.1. Peru Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 55.2. Peru Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 55.3. Peru Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

56. Middle East Cancer Diagnostics Market

  • 56.1. Middle East Cancer Diagnostics Market Overview
  • 56.2. Middle East Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 56.3. Middle East Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 56.4. Middle East Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

57. Saudi Arabia Cancer Diagnostics Market

  • 57.1. Saudi Arabia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 57.2. Saudi Arabia Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 57.3. Saudi Arabia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

58. Israel Cancer Diagnostics Market

  • 58.1. Israel Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 58.2. Israel Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 58.3. Israel Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

59. Iran Cancer Diagnostics Market

  • 59.1. Iran Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 59.2. Iran Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 59.3. Iran Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

60. Turkey Cancer Diagnostics Market

  • 60.1. Turkey Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 60.2. Turkey Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 60.3. Turkey Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

61. United Arab Emirates Cancer Diagnostics Market

  • 61.1. United Arab Emirates Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 61.2. United Arab Emirates Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 61.3. United Arab Emirates Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

62. Africa Cancer Diagnostics Market

  • 62.1. Africa Cancer Diagnostics Market Overview
  • 62.2. Africa Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 62.3. Africa Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 62.4. Africa Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

63. Egypt Cancer Diagnostics Market

  • 63.1. Egypt Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 63.2. Egypt Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 63.3. Egypt Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

64. Nigeria Cancer Diagnostics Market

  • 64.1. Nigeria Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 64.2. Nigeria Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 64.3. Nigeria Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

65. South Africa Cancer Diagnostics Market

  • 65.1. South Africa Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 65.2. South Africa Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 65.3. South Africa Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

66. Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 66.1. Cancer Diagnostics Market Competitive Landscape
  • 66.2. Cancer Diagnostics Market Company Profiles
    • 66.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.2. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.3. Hologic Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.4. GE Healthcare Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.5. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis

67. Cancer Diagnostics Market Other Major And Innovative Companies

  • 67.1. Siemens Healthcare GmbH
  • 67.2. Accuray
  • 67.3. Elekta AB
  • 67.4. C.R. Bard Inc.
  • 67.5. Biogenex Laboratories
  • 67.6. Eckert & Ziegler BEBIG
  • 67.7. Veracyte
  • 67.8. PathAI
  • 67.9. Bio-Rad Laboratories
  • 67.10. Biochain
  • 67.11. DiagnoCure
  • 67.12. Illumina
  • 67.13. Myriad Genetics
  • 67.14. CompanionDx
  • 67.15. Epic Sciences

68. Global Cancer Diagnostics Market Competitive Benchmarking And Dashboard

69. Key Mergers And Acquisitions In The Cancer Diagnostics Market

70. Recent Developments In The Cancer Diagnostics Market

71. Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 71.1 Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 71.2 Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 71.3 Cancer Diagnostics Market In 2029 - Growth Strategies
    • 71.3.1 Market Trend Based Strategies
    • 71.3.2 Competitor Strategies

72. Appendix

  • 72.1. Abbreviations
  • 72.2. Currencies
  • 72.3. Historic And Forecast Inflation Rates
  • 72.4. Research Inquiries
  • 72.5. The Business Research Company
  • 72.6. Copyright And Disclaimer